59633-88-4

Basic information

• Product Name: Cyclohexene, 2-(bromomethyl)-1,3,3-trimethyl-
• CAS NO: 59633-88-4
• Molecular Formula: C10H17Br
• Molecular Weight: 217.149
• Mol File: 59633-88-4.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Cyclohexene, 2-(bromomethyl)-1,3,3-trimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexene, 2-(bromomethyl)-1,3,3-trimethyl-(59633-88-4)
• EPA Substance Registry System: Cyclohexene, 2-(bromomethyl)-1,3,3-trimethyl-(59633-88-4)

Safety Data

• Hazardous Substances Data: 59633-88-4(Hazardous Substances Data)

Upstream product

• 49815-58-9 6,6-dimethyl-2-methyl-1-cyclohexene-1-carboxylic acid methyl ester 
• 432-25-7 2,6,6-trimethylcyclohex-1-enecarbaldehyde 
• 60714-17-2 1,1-dimethyl-2,3-bis(methylene)cyclohexane 
• 472-20-8 β-cyclogeraniol 
• 870-63-3 prenyl bromide 
• 71135-95-0 methyl 2,2-dimethyl-6-oxocyclohexanecarboxylate 
• 53067-23-5 methyl 7-methyl-3-oxooct-6-enoate 
• 79-77-6 (E)-β-ionone 
• 141-27-5 3,7-dimethyl-2,6-octadienal 

Downstream Products

• 59633-89-5 3-oxo-5-(2,6,6-trimethyl-cyclohex-1-enyl)-pentanoic acid methyl ester 
• 56691-74-8 {[(2,6,6-trimethyl-1-cyclohexen-1-yl)methyl]sulfonyl}benzene 
• 122131-12-8 2,5-bis(methoxymethoxy)-1-methyl-3-(2,6,6-trimethylcyclohex-1-enylmethyl)benzene 
• 142528-93-6 1,2-bis-(2,6,6-trimethyl-cyclohex-1-enyl)-ethane 
• 142528-94-7 1,5-Bis-(2,6,6-trimethyl-cyclohex-1-enyl)-pentan-3-one 
• 3899-20-5 ethyl (all-E)-retinoate 
• 351875-34-8 7-cis-ethyl retinoate 
• 57576-15-5 (2,6,6-trimethylcyclohex-1-enyl)acetonitrile 
• 472-68-4 (2,6,6-trimethylcyclohex-1-enyl)acetic acid 
• 514-62-5 (+/-)-ferruginol 
• 3772-54-1 (+/-)-nimbiol methyl ether 
• 113332-25-5 (+/-)-nimbidiol 
• 147593-13-3 4-Hydroxy-5,6-dimethyl-3-(2,6,6-trimethyl-cyclohex-1-enylmethyl)-pyran-2-one 
• 59633-91-9 8ξ-hydroxy-9β-hydroxymethyl-(4α,4β),10β-trimethyl-(trans)-decahydronaphthalene 

Relevant articles and documents

Ligand-based rational design, synthesis and evaluation of novel potential chemical chaperones for opsin

Inherited blinding diseases retinitis pigmentosa (RP) and a subset of Leber's congenital amaurosis (LCA) are caused by the misfolding and mistrafficking of rhodopsin molecules, which aggregate and accumulate in the endoplasmic reticulum (ER), leading to photoreceptor cell death. One potential therapeutic strategy to prevent the loss of photoreceptors in these conditions is to identify opsin-binding compounds that act as chemical chaperones for opsin, aiding its proper folding and trafficking to the outer cell membrane. Aiming to identify novel compounds with such effect, a rational ligand-based approach was applied to the structure of the visual pigment chromophore, 11-cis-retinal, and its locked analogue 11-cis-6mr-retinal. Following molecular docking studies on the main chromophore binding site of rhodopsin, 49 novel compounds were synthesized according to optimized one-to seven-step synthetic routes. These agents were evaluated for their ability to compete for the chromophore binding site of opsin, and their capacity to increase the trafficking of the P23H opsin mutant from the ER to the cell membrane. Different new molecules displayed an effect in at least one assay, acting either as chemical chaperones or as stabilizers of the 9-cis-retinal-rhodopsin complex. These compounds could provide the basis to develop novel therapeutics for RP and LCA.

VISUAL CYCLE MODULATORS

A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a retinal sequestering compound of formula (I).

SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS

The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.